ARCHIVES

Drug Development Budget Cuts Force Early End To P388 Screening Contracts

This article is from The Cancer Letter archive.

Vol. 13 No. 02 | January 9, 1987

Download PDF Visit The Full Archive

Related Articles

NSABP Objects to “Closed Process” For Review Of P-4 Breast Cancer Chemoprevention Trial.

April 20, 2007

Pfizer’s Withdrawal Of Mylotarg Signals Stronger FDA Resolve To Monitor Confirmatory Studies

June 25, 2010

340B Drug Discount Program: HRSA Defends Orphan Drug Rule

June 20, 2014

Clinton Budget For NIH “Disappointing,” AACR executive Director Says

May 7, 1993

HCFA Sees Applications For DRGs And Research

September 27, 1985

Reimbursement Of Some Anticancer Drugs Expected To Drop Sharply Under HHS Policy.

June 30, 2000